HomeCompareBDR vs PFE

BDR vs PFE: Dividend Comparison 2026

BDR yields 655.74% · PFE yields 6.20%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 BDR wins by $531184.30M in total portfolio value
10 years
BDR
BDR
● Live price
655.74%
Share price
$0.31
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$531184.35M
Annual income
$408,606,309,899.83
Full BDR calculator →
PFE
Pfizer Inc.
● Live price
6.20%
Share price
$27.76
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$51.1K
Annual income
$27,210.54
Full PFE calculator →

Portfolio growth — BDR vs PFE

📍 BDR pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodBDRPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, BDR + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
BDR pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BDR
Annual income on $10K today (after 15% tax)
$55,737.70/yr
After 10yr DRIP, annual income (after tax)
$347,315,363,414.86/yr
PFE
Annual income on $10K today (after 15% tax)
$526.66/yr
After 10yr DRIP, annual income (after tax)
$23,128.96/yr
At 15% tax rate, BDR beats the other by $347,315,340,285.90/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BDR + PFE for your $10,000?

BDR: 50%PFE: 50%
100% PFE50/50100% BDR
Portfolio after 10yr
$265592.20M
Annual income
$204,303,168,555.18/yr
Blended yield
76.92%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

BDR
No analyst data
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-0.9% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BDR buys
0
PFE buys
0
No recent congressional trades found for BDR or PFE in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricBDRPFE
Forward yield655.74%6.20%
Annual dividend / share$2.00$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%13.2%
Portfolio after 10y$531184.35M$51.1K
Annual income after 10y$408,606,309,899.83$27,210.54
Total dividends collected$521134.98M$60.1K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: BDR vs PFE ($10,000, DRIP)

YearBDR PortfolioBDR Income/yrPFE PortfolioPFE Income/yrGap
1← crossover$76,274$65,573.77$9,161$701.38+$67.1KBDR
2$549,048$467,435.39$8,610$859.79+$540.4KBDR
3$3,732,138$3,144,656.22$8,366$1,081.25+$3.72MBDR
4$23,970,675$19,977,287.04$8,483$1,405.66+$23.96MBDR
5$145,564,116$119,915,494.45$9,084$1,907.24+$145.56MBDR
6$836,312,314$680,558,709.22$10,418$2,732.78+$836.30MBDR
7$4,549,085,040$3,654,230,864.88$13,007$4,193.56+$4549.07MBDR
8$23,444,186,795$18,576,665,801.85$18,010$7,005.87+$23444.17MBDR
9$114,558,920,290$89,473,640,419.13$28,216$12,979.89+$114558.89MBDR
10$531,184,354,610$408,606,309,899.83$51,081$27,210.54+$531184.30MBDR

BDR vs PFE: Complete Analysis 2026

BDRStock

Blonder Tongue Laboratories, Inc., a technology-development and manufacturing company, provides television (TV) signal encoding, transcoding, digital transport, and broadband product solutions in the United States. It offers encoders/transcoders, such as 4K/ultra-high definition, high definition and standard definition, MPEG-2, MPEG-4/H.264, and HEVC/H.265 capable encoders and transcoders; and QPSK and 8PSK, and QAM transcoders. The company also provides NXG IP digital video processing and headend products, including IPTV format conversions and simulcast use cases. In addition, it offers coax distribution products comprising broadband amplifiers, directional taps, splitters, and wall outlets; coax distribution products are either mounted on exterior utility poles or encased in pedestals, vaults, or other security devices in cable television systems; distribution system is enclosed within the walls of the building or added to an existing structure using various techniques to hide the coax cable and devices in SMB systems; and non-passive devices for signal distributed from the headend is of sufficient strength when it arrives at its final destination to provide audio/video images. Further, the company provides CPE products consisting of Android-based IPTV set top boxes. Additionally, it offers digital modulation products, such as Aircastertm ATSC, QAM, and IP trans-modulator series of products allow the user to create a line up from off-air and/or cable feeds for coax IP distribution; Edge QAM devices that accept Ethernet input and capture MPEG over IP transport streams, decrypt service provider conditional access or content protection, and insert proprietary conditional access; DOCSIS data products; service level agreements and services; and analog modulation, fiber, and miscellaneous products and services, as well as test and measurement instruments, and contract manufacturing services. The company was founded in 1950 and is headquartered in Old Bridge, New Jersey.

Full BDR Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this BDR vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BDR vs SCHDBDR vs JEPIBDR vs OBDR vs KOBDR vs MAINBDR vs JNJBDR vs MRKBDR vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.